8
Validated projects
Validated across 8 projects, with 7 projects yielding hit antibodies, corresponding to a success rate of approximately 87.5%.
Technical Validation
Evaluating AI Antibody Design Through Validation Cases
Click.mAb. is designed not only to generate candidate sequences, but also to connect epitope selection, sequence generation, structural assessment, and experimental validation into a reviewable R&D workflow. The following data come from representative validation cases.
24+
Binding hits
Representative cases have produced more than 24 experimentally confirmed binding candidates.
µM–nM
Affinity range
Candidate antibody affinities span the micromolar to nanomolar range.
Cryo-EM
Structural confirmation
A representative case confirmed the target epitope by cryo-EM.
Representative Evidence
De Novo Design Validation
In epitope-specific de novo design cases, the platform generates candidate sequences around target epitopes and validates results with BLI, blocking assays, and structural biology. Across 8 validated projects, 7 yielded hit antibodies, corresponding to a success rate of approximately 87.5%.
Affinity Maturation Validation
Wet-lab validation of affinity maturation showed that the best matured antibody achieved a KD of 0.091 nM, representing a 12.2× improvement over the parent antibody, with 31 out of 32 candidates successfully expressed. Structure-driven cooperative mutation analysis enables significant affinity gains from small candidate libraries.
Humanization Performance
Representative antibody humanization cases reached 90%–95% humanness, while representative nanobody humanization cases reached 89%–94% humanness while preserving or improving affinity in selected sequences.
CDR Diversity Engineering
For a 2 nM antibody based on a known active sequence targeting Trop2, CDR diversity engineering achieved CDR identity as low as 57%, meeting the target threshold of ≤70%. The result included 2 antibodies within 50% of parental affinity, 11 candidates with normal expression, and 8 candidates with SEC-HPLC purity matching or exceeding the parent antibody, successfully meeting the sequence diversification goal.
R&D Workflow Continuity
The platform outputs candidate molecules, sequence analyses, structural assessments, and reports to support expression, screening, affinity optimization, and project review.
Related Capabilities
Do these data represent every project outcome?
No. Antibody R&D outcomes depend on target properties, epitope accessibility, assay systems, and project goals. These are representative cases that show validated directions and capability boundaries.
Can existing antibodies be further optimized?
Yes. The platform supports affinity maturation, antibody humanization, and nanobody humanization, including structural assessment, mutation suggestions, and candidate ranking for existing sequences.